Amalgamated Bank Acquires 2,354 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Amalgamated Bank lifted its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 55.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,566 shares of the company’s stock after purchasing an additional 2,354 shares during the period. Amalgamated Bank’s holdings in Hims & Hers Health were worth $133,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Mercer Global Advisors Inc. ADV grew its holdings in Hims & Hers Health by 1,391.3% during the second quarter. Mercer Global Advisors Inc. ADV now owns 149,176 shares of the company’s stock valued at $3,012,000 after purchasing an additional 139,173 shares during the period. Virtu Financial LLC boosted its position in shares of Hims & Hers Health by 265.9% during the second quarter. Virtu Financial LLC now owns 150,911 shares of the company’s stock worth $3,047,000 after purchasing an additional 109,666 shares in the last quarter. WealthPLAN Partners LLC acquired a new position in shares of Hims & Hers Health in the 2nd quarter valued at $1,022,000. Renaissance Technologies LLC increased its position in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares in the last quarter. Finally, Citizens Financial Group Inc. RI acquired a new stake in Hims & Hers Health during the 2nd quarter worth $614,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Truist Financial raised their price target on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Jefferies Financial Group raised their price objective on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, June 27th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, Bank of America cut their price target on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, September 13th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.86.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $16.47, for a total value of $3,110,985.36. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at $551,777.94. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the completion of the sale, the chief executive officer now owns 33,502 shares in the company, valued at $551,777.94. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Melissa Baird sold 17,625 shares of the stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $20.51, for a total value of $361,488.75. Following the transaction, the chief operating officer now owns 585,800 shares in the company, valued at approximately $12,014,758. The disclosure for this sale can be found here. Insiders have sold 542,585 shares of company stock worth $8,751,851 over the last 90 days. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Up 4.9 %

Shares of HIMS opened at $19.32 on Wednesday. The company’s fifty day simple moving average is $16.82 and its 200 day simple moving average is $17.25. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $25.74. The company has a market cap of $4.15 billion, a price-to-earnings ratio of -1,931.50 and a beta of 1.05.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. During the same period in the previous year, the business earned ($0.03) EPS. Hims & Hers Health’s revenue for the quarter was up 51.8% compared to the same quarter last year. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.